The company is working on expanding its flagship LiverMultiScan product, a tool used to diagnose and assess liver disease.
The second tranche of series C funding brings the company’s total series C round to $55 million, according to a March 15 Perspectum news release.
Since the company’s inception, it has raised $140 million. Oppenheimer led the latest series C investment round.
